Citigroup Reiterates Neutral Rating on ResMed Inc. (RMD)

Market Context

ResMed Inc. operates in the Healthcare sector. The stock currently trades at $229.94 with a market capitalization of $37.0B. The stock has declined 7.7% over the past 52 weeks.

Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ResMed Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ResMed Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 30, 2026	Citigroup	Neutral	N/A
Oct 30, 2026	Wells Fargo	Equal-Weight	N/A
Oct 30, 2026	RBC Capital	Outperform	N/A
Oct 30, 2026	Keybanc	Overweight	N/A
Sep 15, 2026	RBC Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View RMD Stock Page